MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
AbCellera Biologics Total Non Current Liabilities 2011-2026 | ABCL
Annual Total Non Current Liabilities AbCellera Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 326 M | 228 M | 217 M | 189 M | 172 M | 71.5 M | 5.34 M | 3.45 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 326 M | 3.45 M | 152 M |
Quarterly Total Non Current Liabilities AbCellera Biologics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 323 M | 328 M | 246 M | 228 M | 235 M | 231 M | 228 M | 217 M | 219 M | 223 M | 200 M | 189 M | 196 M | 160 M | 171 M | 172 M | 170 M | 114 M | 83 M | 71.5 M | 71.5 M | 71.5 M | 71.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 328 M | 71.5 M | 184 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B |  France |
 |
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.38 | -0.58 % | $ 367 M |  Britain |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.72 | 3.24 % | $ 8.95 B |  Australia |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
42.1 M | $ 2.6 | -2.29 % | $ 16.3 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
24.6 M | $ 6.31 | -1.79 % | $ 180 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Fulcrum Therapeutics
FULC
|
5.54 M | $ 7.79 | -0.51 % | $ 494 K | USA |
 |
Galectin Therapeutics
GALT
|
52 K | $ 2.22 | -13.28 % | $ 142 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
Gilead Sciences
GILD
|
29.2 B | $ 138.97 | -0.83 % | $ 173 B | USA |
 |
Genmab A/S
GMAB
|
769 M | $ 27.51 | -0.86 % | $ 17.3 B |  Danmark |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Gossamer Bio
GOSS
|
37.2 M | $ 0.32 | -6.5 % | $ 73.1 M | USA |
 |
Grifols, S.A.
GRFS
|
7.22 B | $ 8.03 | -2.43 % | $ 6.83 B |  Spain |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
GT Biopharma
GTBP
|
714 K | $ 0.41 | -6.9 % | $ 2.26 M | USA |
 |
Halozyme Therapeutics
HALO
|
388 M | $ 63.53 | 0.71 % | $ 7.61 B | USA |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
341 M | $ 89.39 | -2.07 % | $ 27.2 B | Germany |
 |
Coherus BioSciences
CHRS
|
189 M | $ 1.64 | -2.1 % | $ 192 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
50 K | $ 3.53 | -0.28 % | $ 238 B | Britain |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
149 M | $ 27.66 | -0.18 % | $ 1.59 B | USA |
 |
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
604 M | $ 319.97 | -3.14 % | $ 41.9 B | USA |
 |
iBio
IBIO
|
32.3 M | $ 2.11 | 3.69 % | $ 22.2 M | USA |
 |
ImmuCell Corporation
ICCC
|
11.5 M | $ 6.6 | -0.15 % | $ 59.6 M | USA |
 |
IDEAYA Biosciences
IDYA
|
5.66 M | $ 30.88 | -4.51 % | $ 2.73 B | USA |
 |
InflaRx N.V.
IFRX
|
254 K | $ 0.97 | 2.89 % | $ 152 M | Germany |
 |
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | USA |
 |
Immutep Limited
IMMP
|
10.9 M | $ 0.35 | -3.08 % | $ 1.08 B | Australia |
 |
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | USA |
 |
Immuron Limited
IMRN
|
175 K | $ 0.82 | -0.12 % | $ 6.29 M | Australia |
 |
Incyte Corporation
INCY
|
315 M | $ 94.06 | -0.84 % | $ 18.4 B | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |